NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NEO

Neogenomics Inc

Jul 01 • 12:46PM ET

7.46

Dollar change +0.15
Percentage change 2.06	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN LH DGX BIO QGEN EXAS NVCR GH TMO A

| Held by: IJR VTI VB IWM VXF VBK SPSM IWN IJS VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	1.38%	Shs Outstand	128.36M	Perf Week	3.19%
Market Cap	960.18M	Forward P/E	24.90	EPS next Y	0.30	Insider Trans	4.42%	Shs Float	126.92M	Perf Month	2.48%
Enterprise Value	1.21B	PEG	-	EPS next Q	0.03	Inst Own	98.81%	Short Float	3.40%	Perf Quarter	-21.38%
Income	-77.59M	P/S	1.43	EPS this Y	39.11%	Inst Trans	2.64%	Short Ratio	1.86	Perf Half Y	-56.82%
Sales	672.36M	P/B	1.08	EPS next Y	95.85%	ROA	-4.79%	Short Interest	4.31M	Perf YTD	-54.73%
Book/sh	6.92	P/C	2.68	EPS next 5Y	66.44%	ROE	-8.57%	52W High	19.11 -60.97%	Perf Year	-44.07%
Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	-107.48% -	ROIC	-6.02%	52W Low	6.08 22.71%	Perf 3Y	-23.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.90% 10.07%	Gross Margin	41.52%	Volatility	4.83% 5.15%	Perf 5Y	-73.14%
Dividend TTM	-	EV/Sales	1.79	EPS Y/Y TTM	8.79%	Oper. Margin	-12.01%	ATR (14)	0.41	Perf 10Y	37.40%
Dividend Ex-Date	-	Quick Ratio	1.94	Sales Y/Y TTM	10.10%	Profit Margin	-11.54%	RSI (14)	50.81	Recom	1.93
Dividend Gr. 3/5Y	- -	Current Ratio	2.05	EPS Q/Q	5.17%	SMA20	2.22%	Beta	1.62	Target Price	10.67
Payout	-	Debt/Eq	0.68	Sales Q/Q	7.55%	SMA50	-4.07%	Rel Volume	0.48	Prev Close	7.31
Employees	2200	LT Debt/Eq	0.45	Earnings	Apr 29 BMO	SMA200	-39.23%	Avg Volume	2.32M	Price	7.46
IPO	Nov 10, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% -1.49%	Trades		Volume	590,823	Change	2.06%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Initiated	Guggenheim	Neutral
Apr-30-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy	$22
May-01-24	Resumed	Craig Hallum	Buy	$26
Dec-29-23	Reiterated	BTIG Research	Buy	$25 → $21
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight	$18
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy	$25
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy	$20
Feb-01-23	Upgrade	Needham	Hold → Buy	$15
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight	$13
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight	$34 → $16
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral	$25 → $18
Jan-18-22	Resumed	Stephens	Overweight	$40
Dec-16-21	Initiated	Cowen	Outperform	$42
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$53

Show Previous Ratings

Today 07:05AM	NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 (Business Wire)
Jun-30-25 07:05AM	NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care (Business Wire)
Jun-24-25 04:27PM	3 Hot Trades for Insiders, But Are They Good Buys for Investors? (MarketBeat)
02:19PM	5 Insightful Analyst Questions From NeoGenomics's Q1 Earnings Call (StockStory)
07:05AM	NeoGenomics Appoints Dr. Marjorie Green to Board of Directors (Business Wire)
07:10AM	Loading…
May-28-25 07:10AM	NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 (Business Wire)
May-23-25 10:09AM	NeoGenomics introduces c-MET companion diagnostic for NSCLC (Medical Device Network)
May-22-25 07:10AM	NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer (Business Wire)
May-20-25 07:05AM	NeoGenomics to Participate in Upcoming June Investor Conferences (Business Wire)
12:40AM	3 Healthcare Stocks with Mounting Challenges (StockStory)
May-06-25 09:30AM	It's Not Too Late to Jump on These Under-the-Radar Momentum Plays (MarketBeat)
May-05-25 12:34AM	3 Small-Cap Stocks Walking a Fine Line (StockStory)
May-01-25 11:55AM	NeoGenomics price target lowered to $10 from $17 at Morgan Stanley (TipRanks) +13.53%
07:05AM	NeoGenomics Pays Off 1.25% Convertible Senior Notes (Business Wire)
Apr-30-25 09:00AM	NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) (Seeking Alpha)
03:09AM	Loading…
03:09AM	NeoGenomics Inc (NEO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 03:49PM	Why NeoGenomics (NEO) Stock Is Nosediving (StockStory) -34.00%
12:18PM	NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:40AM	NeoGenomics (NEO) Reports Break-Even Earnings for Q1 (Zacks)
08:00AM	NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform (PR Newswire)
07:56AM	NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops (StockStory)
07:42AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2025 Results (Business Wire)
Apr-28-25 03:01AM	NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-23-25 10:01AM	Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-22-25 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:05AM	NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting (Business Wire)
Apr-08-25 07:05AM	NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 (Business Wire) -7.13%
Apr-07-25 07:05AM	NeoGenomics Completes Acquisition of Pathline (Business Wire)
Apr-03-25 05:06AM	Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) (StockStory) -7.43%
07:05AM	Loading…
Apr-01-25 07:05AM	Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics (Business Wire)
Mar-21-25 05:10AM	3 Reasons to Sell NEO and 1 Stock to Buy Instead (StockStory)
Mar-18-25 07:05AM	NeoGenomics Appoints Warren Stone as President & Chief Operating Officer (Business Wire)
Mar-14-25 05:08AM	Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX) (StockStory)
Mar-12-25 12:43PM	3 Small-Cap Stocks in Hot Water (StockStory) -5.97%
Mar-10-25 07:00AM	NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline (Business Wire) -10.05%
Feb-28-25 08:02AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Feb-24-25 07:05AM	NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
Feb-19-25 02:03AM	NeoGenomics Inc (NEO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-18-25 11:33PM	Q4 2024 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents) -13.97%
12:46PM	Why NeoGenomics (NEO) Shares Are Trading Lower Today (StockStory)
08:15AM	NeoGenomics (NEO) Tops Q4 Earnings Estimates (Zacks)
07:24AM	NeoGenomics: Q4 Earnings Snapshot (Associated Press Finance)
07:13AM	NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets (StockStory)
07:05AM	NeoGenomics Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-17-25 08:13AM	NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-12-25 09:56AM	Q4 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
Jan-30-25 09:05AM	PacBio Announces Appointment of Chris Smith to Board of Directors (GlobeNewswire)
Jan-29-25 08:05AM	NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 (Business Wire)
Jan-15-25 04:24PM	NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance (Investor's Business Daily) +6.75%
10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:05AM	NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan (Business Wire)
04:53AM	NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jan-14-25 07:30AM	Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients (GlobeNewswire) +9.11%
Jan-10-25 07:05AM	NeoGenomics Announces Chief Executive Officer Succession (Business Wire) -20.63%
Jan-06-25 07:55AM	NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-24 12:00PM	NeoGenomics (NEO) Upgraded to Buy: Here's Why (Zacks)
Dec-11-24 08:05AM	NeoGenomics Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma (Business Wire)
Dec-09-24 08:10AM	NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting (Business Wire)
Dec-05-24 07:00AM	ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research (Business Wire)
Nov-19-24 08:15AM	NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Nov-14-24 08:10AM	Felicia Williams Joins NeoGenomics Board of Directors (Business Wire)
Nov-08-24 07:00AM	NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-06-24 12:00PM	NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
02:24AM	Q3 2024 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-05-24 10:00AM	NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +5.59%
07:23AM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	NeoGenomics Reports Third Quarter 2024 Results (Business Wire)
Nov-04-24 09:55AM	Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade (Zacks)
Oct-23-24 05:37AM	NeoGenomics gains conditional approval for solid tumour assays in New York (Medical Device Network)
Oct-22-24 08:10AM	NeoGenomics Receives New York State Approval for Neo Comprehensive Solid Tumor Test (Business Wire)
Oct-15-24 07:30AM	NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 (Business Wire)
Oct-08-24 09:55AM	NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:10AM	NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia (Business Wire)
Sep-23-24 06:47PM	NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation (Business Wire)
Sep-11-24 08:05AM	NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Aug-29-24 08:05AM	NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Jul-29-24 06:00PM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings (Zacks) +17.96%
04:33PM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	NeoGenomics Reports Second Quarter 2024 Results (Business Wire)
Jul-20-24 08:09AM	Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years? (Insider Monkey)
Jul-09-24 07:00AM	NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024 (Business Wire)
Jun-13-24 08:00AM	Fort Myers Mayor to Proclaim June as NeoGenomics Commitment to Cancer Month (Business Wire)
Jun-10-24 01:00AM	Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing (GlobeNewswire)
May-28-24 08:05AM	NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management (Business Wire)
May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.44%
May-01-24 03:04AM	NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
Apr-30-24 11:53AM	NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -8.54%
11:25AM	Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating (MT Newswires)
10:30AM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings (Zacks)
08:52AM	NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
08:40AM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:37AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2024 Results (Business Wire)
Apr-23-24 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) +5.51%
Apr-18-24 07:05AM	NeoGenomics Announces Senior Leadership Promotions (Business Wire)
Apr-09-24 07:00AM	NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024 (Business Wire)
Mar-27-24 08:30AM	NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting (Business Wire)
Mar-20-24 12:00PM	All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy (Zacks) +5.57%

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Felicia	Director	Jun 01 '25	Option Exercise	0.00	7,160	0	7,160	Jun 03 04:08 PM
KANOVSKY STEPHEN M	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	52,344	Jun 03 04:08 PM
Kelly Michael Aaron	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	44,009	Jun 03 04:08 PM
TETRAULT LYNN A.	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	73,652	Jun 03 04:07 PM
Floegel Elizabeth	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	23,590	Jun 03 04:07 PM
Gunn Neil	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	28,100	Jun 03 04:07 PM
Zook Anthony P.	Chief Executive Officer	Jun 01 '25	Option Exercise	0.00	12,254	0	23,590	Jun 03 04:06 PM
Perez David Brian	Director	Jun 01 '25	Option Exercise	0.00	12,254	0	33,890	Jun 03 04:06 PM
Kelly Michael Aaron	Director	May 27 '25	Buy	7.60	5,000	38,000	5,000	May 28 04:07 PM
Olivo Alicia C	EVP, GC & Business Development	May 11 '25	Option Exercise	0.00	6,503	0	51,204	May 13 04:06 PM
Sherman Jeffrey Scott	Chief Financial Officer	May 11 '25	Option Exercise	0.00	13,005	0	171,499	May 13 04:06 PM
Stone Warren	Pres & Chief Operating Officer	May 11 '25	Option Exercise	0.00	9,613	0	104,921	May 13 04:05 PM
Stone Warren	Pres & Chief Operating Officer	May 12 '25	Buy	8.58	5,700	48,895	108,280	May 13 04:05 PM
TETRAULT LYNN A.	Director	May 09 '25	Buy	8.14	7,000	56,974	7,000	May 09 05:26 PM
KANOVSKY STEPHEN M	Director	May 07 '25	Buy	7.78	4,000	31,124	40,090	May 09 05:24 PM
Zook Anthony P.	Chief Executive Officer	May 06 '25	Buy	7.88	18,900	148,919	18,900	May 08 04:13 PM
Perez David Brian	Director	May 05 '25	Buy	7.63	10,000	76,300	10,000	May 07 04:05 PM
Gunn Neil	Director	May 05 '25	Buy	7.75	4,510	34,977	15,846	May 07 04:05 PM
Sherman Jeffrey Scott	Chief Financial Officer	May 02 '25	Buy	7.51	20,000	150,104	158,494	May 06 04:08 PM
Stone Warren	Pres & Chief Operating Officer	May 02 '25	Option Exercise	0.00	5,969	0	96,762	May 06 04:07 PM
Aunan Greg D	Chief Accounting Officer	May 02 '25	Option Exercise	0.00	5,372	0	18,888	May 05 04:06 PM
Olivo Alicia C	EVP, GC & Business Development	Feb 23 '25	Option Exercise	0.00	8,443	0	47,857	Feb 25 04:41 PM
Harris Melody	Chf Ops Off, Pres, Informatics	Feb 23 '25	Option Exercise	0.00	8,443	0	111,811	Feb 25 04:40 PM
Stone Warren	Chief Commerical Officer	Feb 23 '25	Option Exercise	0.00	8,443	0	93,265	Feb 25 04:39 PM
Sherman Jeffrey Scott	Chief Financial Officer	Feb 23 '25	Option Exercise	0.00	15,535	0	141,271	Feb 25 04:38 PM
Smith Christopher M	Chief Executive Officer	Feb 23 '25	Option Exercise	0.00	57,413	0	655,652	Feb 25 04:37 PM
Olivo Alicia C	General Counsel	Nov 15 '24	Sale	15.36	5,175	79,475	37,129	Nov 19 05:43 PM
ALICIA OLIVO	Officer	Nov 15 '24	Proposed Sale	15.79	5,175	81,713		Nov 15 04:35 PM
Olivo Alicia C	General Counsel	Aug 15 '24	Sale	16.05	1,040	16,695	43,813	Aug 19 04:17 PM
ALICIA OLIVO	Officer	Aug 15 '24	Proposed Sale	15.82	1,040	16,453		Aug 15 04:29 PM
BRUCE K CROWTHER	Officer	Aug 15 '24	Proposed Sale	15.95	8,353	133,243		Aug 15 04:12 PM
Zook Anthony P.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:40 PM
TETRAULT LYNN A.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	61,398	Aug 13 04:37 PM
Perez David Brian	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	21,636	Aug 13 04:34 PM
Kelly Michael Aaron	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	31,755	Aug 13 04:32 PM
KANOVSKY STEPHEN M	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	36,090	Aug 13 04:27 PM
HANNAH ALISON L.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	118,769	Aug 13 04:24 PM
Gunn Neil	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:21 PM
Floegel Elizabeth	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NEO

Neogenomics Inc

Upgrade your FINVIZ experience